Clin2
NCT07333196Possibly a fitNot yet recruiting

Observational study for people with neuroimmune conditions

Multiple SclerosisNMO Spectrum DisorderAutoimmune EncephalitisMyelin Oligodendrocyte Glycoprotein Antibody-associated DiseaseAutoimmune NodopathyAcute Inflammatory Demyelinating PolyradiculoneuropathyChronic Inflammatory Demyelinating PolyradiculoneuropathyMyasthenia Gravis

Part of Bones, joints & muscles, Brain & nervous system, Cancer, Eyes & vision, Immune system & allergy clinical trials.

This study is a long-term observational study—it does not test a new drug but follows people with certain nerve and immune conditions (like multiple sclerosis, myasthenia gravis, and others) to learn more about how these diseases progress. By joining, you help researchers gather valuable data that could improve care for others with similar conditions.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
1,550 people
Ages
18 years to 80 years
Study type
Observational

Who can take part

  • You must be between 18 and 80 years old.
  • You need to be diagnosed with one of the following conditions: multiple sclerosis, neuromyelitis optica spectrum disorder (NMOSD), MOG antibody disease, autoimmune encephalitis, Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis, or inflammatory myopathy (such as dermatomyositis).
  • You must be able to understand the purpose and risks of the study and provide written consent.
  • This is an observational study, so you won't receive any experimental treatments, but you will be followed over time.
  • There are no specific exclusion criteria, but your doctor must confirm you are suitable to enroll.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06502015Recruiting
Biomarkers in nervous system autoimmune diseases

This study looks for biomarkers (biological clues) in people with autoimmune diseases of the nervous system. It aims to discover better ways to diagnose and treat these conditions.

Wuhan
NCT06541626Recruiting
Study of CNS inflammatory demyelinating diseases

This study follows people with certain inflammatory conditions of the brain and spinal cord (like MS, NMOSD, or MOGAD) to learn more about their disease. If you join, you will help researchers understand these conditions better.

Guangzhou, Guangdong
NCT04106830Recruiting
Study to follow neuroinflammation and demyelination diseases with imaging

This study builds a China-based group of people with neuroinflammatory and demyelination diseases and collects health and MRI (brain scan) information. It may help doctors better understand these conditions over time and improve future treatments.

Beijing, Beijing Municipality
NCT00794352Recruiting
Studying immune brain and nerve conditions with tests and samples

This study looks at how immune-related brain or spinal cord illness shows up using exams, MRI scans, and sometimes a spinal fluid test (lumbar puncture), plus collected blood and other samples. It may help researchers better understand these conditions and improve future diagnosis or treatments.

Bethesda, Maryland
NCT05154370Recruiting
Registry for neuroinflammation diseases and diagnosis categories

This study is a registry that collects information from people diagnosed with certain neuroinflammation conditions. It may help doctors learn how these diseases behave over time and support future research.

Beijing, Beijing Municipality
NCT05204459Recruiting
MRI and eye-scan study for MS and related conditions

This trial uses brain MRI and eye imaging tests to study research markers in people with multiple sclerosis (MS) and related neurologic conditions. It may help researchers better understand these diseases and how they change over time.

Los Angeles, California

Hear when a new Multiple sclerosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.